Kiran Mazumdar-Shaw, executive chairperson of Indian drugmaker Biocon Ltd., outlined her company's ambitious goal to become the world's leading insulin supplier within the next five years. This strategy is driven by the increasing global demand for insulin, particularly in emerging markets, and a simultaneous shift in focus by major pharmaceutical companies towards newer, more profitable metabolic medicines like GLP-1s (glucagon-like peptides).
Biocon, currently the third-largest insulin supplier globally by volume, is significantly expanding its production capacity to seize this market opportunity. Mazumdar-Shaw views the reallocation of resources by pharmaceutical giants like Novo Nordisk A/S and Eli Lilly & Co. from insulin to other diabetes and weight-loss drugs as a "windfall" that allows Biocon to fill a critical market gap and accelerate its insulin business.
In contrast to many pharmaceutical peers racing to enter the crowded GLP-1 market, Biocon is adopting a more measured approach. Mazumdar-Shaw noted that the patent expiry for semaglutide (a key ingredient in drugs like Wegovy and Ozempic) is leading to a highly competitive generic market with prices hitting "rock bottom" in India. Biocon does not plan to sell its generic versions of semaglutide in India but will selectively target markets such as Canada, Latin America, Brazil, the Middle East, and Southeast Asia where it sees viable opportunities.
Mazumdar-Shaw founded Biocon almost 50 years ago from a rented garage. Today, the company boasts a market capitalization exceeding $7 billion. Her personal net worth, derived from stakes in Biocon, Syngene International Ltd., and Narayana Hrudayalaya Ltd., stands at $2.3 billion. She discussed her pioneering journey as a female entrepreneur in India and her vision for biotech sovereignty, particularly concerning AI, as she prepares to hand over her life's work to successors.
